Home » Newsletters » BioWorld Science

BioWorld Science

May 3, 2013

View Archived Issues

New small-molecule enzymatic inhibitors targeting primary human tumors

Adenovirus-based immunotherapy for chronic hepatitis B

New electrochemical immunosensor for diagnosis of inflammatory intestinal disease

Yakult Honsha synthesizes novel protein kinase inhibitors

French team presents new caspase activators

BioSavita and Quanta BioDesign enter collaboration to BioSuperior therapeutics

Dana-Farber and Evotec form oncology collaboration focusing on epigenetic targets

Servier to use Afraxis' ESP Technology for drug discovery

CCT-271850 demonstrates in vitro and in vivo activity

Tolero acquires worldwide license to Sanofi's alvocidib

OGX-427 to be studied as part of combination therapy for pancreatic cancer

Genentech evaluates antibody-drug conjugate for lung and ovarian cancer

Ligand acquires financial rights to portfolio of programs from Selexis

FDA approves use of Actemra in polyarticular juvenile idiopathic arthritis

FDA approves Raptor Pharmaceutical's treatment for nephropathic cystinosis

FDA issues complete response letter declining approval of Probuphine

Roche discloses new CRAC modulators

Novel PDE10A inhibitors prepared by Lundbeck

Enanta Pharmaceuticals synthesizes novel HCV NS5A inhibitors

Ascletis Pharmaceuticals obtains rights to HIV drug in China

DiaMedica begins first-in-human trial of DM-199

Forest Laboratories and Almirall report data from phase III AUGMENT COPD study

Daratumumab receives FDA breakthrough therapy designation

Vyvanse obtains FDA approval for maintenance treatment in children with ADHD

Omadacycline receives another QIDP designation

FDA committee votes against approval of tivozanib

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.